Skip to content
Disclosery

Saturn V Capital Management LP

Follow

13F filer, CIK 1964437, AUSTIN, TX

Saturn V Capital Management LP reported $246,760,882 across 24 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-13. Its ten largest share positions make up 69.44% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001964437-25-000008

Period
2025-06-30
Reported value
$247M
Holdings
24
Top 10 weight
69.44%
New
5
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
JAZZnew+206,952$22M
DYNnew+1,455,429$13.9M
PCVXadded+311,926$10.1M
LENZnew+342,312$10M
NBIXnew+58,181$7.31M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ASNDreduced-161,073-$27.8M
IRONreduced-122,062-$6.46M
MERUS N Vreduced-98,951-$5.2M
SNDXreduced-540,729-$5.06M
SLNreduced-697,726-$4.05M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001964437-25-000008, largest first. % of portfolio is the value over $246,760,882, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
JAZZJAZZ PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 206,952 shares 206,952$22M8.9%newTimeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 511,041 shares; 2024Q4: 509,406 shares; 2025Q1: 518,177 shares; 2025Q2: 396,115 shares 396,115$21M8.5%-122,062Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 889,073 shares; 2025Q1: 2,426,436 shares; 2025Q2: 3,260,570 shares 3,260,570$20.9M8.47%+834,134Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 204,987 shares; 2024Q4: 204,285 shares; 2025Q1: 232,295 shares; 2025Q2: 544,221 shares 544,221$17.7M7.17%+311,926Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,712,899 shares; 2024Q4: 1,498,425 shares; 2025Q1: 1,480,020 shares; 2025Q2: 2,297,524 shares 2,297,524$16.5M6.69%+817,504Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 946,335 shares; 2024Q4: 1,063,783 shares; 2025Q1: 1,093,677 shares; 2025Q2: 1,185,520 shares 1,185,520$15.8M6.41%+91,843Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 520,119 shares; 2024Q4: 593,262 shares; 2025Q1: 577,696 shares; 2025Q2: 586,647 shares 586,647$15.3M6.18%+8,951Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 322,470 shares; 2025Q1: 413,711 shares; 2025Q2: 468,364 shares 468,364$14.7M5.94%+54,653Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,455,429 shares 1,455,429$13.9M5.62%newTimeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 298,974 shares; 2024Q4: 346,111 shares; 2025Q1: 343,849 shares; 2025Q2: 290,784 shares 290,784$13.7M5.56%-53,065Timeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 131,240 shares; 2024Q4: 234,637 shares; 2025Q1: 323,211 shares; 2025Q2: 224,260 shares 224,260$11.8M4.78%-98,951
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 448,692 shares; 2025Q2: 793,327 shares 793,327$10.4M4.22%+344,635Timeline
LENZLENZ THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 342,312 shares 342,312$10M4.07%newTimeline
NBIXNEUROCRINE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 58,181 shares 58,181$7.31M2.96%newTimeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 191,456 shares; 2025Q1: 598,191 shares; 2025Q2: 728,576 shares 728,576$6.76M2.74%+130,385Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 200,285 shares; 2024Q4: 198,977 shares; 2025Q1: 199,264 shares; 2025Q2: 38,191 shares 38,191$6.59M2.67%-161,073Timeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 22,111 shares; 2024Q4: 19,754 shares; 2025Q1: 13,862 shares; 2025Q2: 10,285 shares 10,285$5.67M2.3%-3,577Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 648,019 shares; 2024Q4: 653,071 shares; 2025Q1: 552,926 shares; 2025Q2: 622,479 shares 622,479$4.76M1.93%+69,553Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 501,978 shares; 2024Q4: 988,528 shares; 2025Q1: 1,041,280 shares; 2025Q2: 500,551 shares 500,551$4.69M1.9%-540,729Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 100,000 shares; 2025Q1: 116,353 shares; 2025Q2: 220,695 shares 220,695$4M1.62%+104,342Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 77,297 shares; 2024Q4: 573,022 shares; 2025Q1: 560,979 shares; 2025Q2: 319,348 shares 319,348$1.27M0.51%-241,631Timeline
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 128,917 shares 128,917$1.2M0.49%newTimeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 556,489 shares; 2024Q4: 556,489 shares; 2025Q1: 255,060 shares; 2025Q2: 62,793 shares 62,793$710K0.29%-192,267Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 481,127 shares; 2024Q4: 395,024 shares; 2025Q1: 732,463 shares; 2025Q2: 34,737 shares 34,737$201K0.08%-697,726Timeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CRNXCRINETICS PHARMACEUTICALS IN59,017$1.98Mshares
INOZYME PHARMA INCINOZYME PHARMA INC499,254$454Kshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001964437-25-000008 base2025-08-13acceptance time not in the bulk data set